Analysts’ Top Healthcare Picks: Merck & Company (MRK), Regeneron (REGN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK) and Regeneron (REGN) with bullish sentiments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Merck & Company (MRK)
In a report released yesterday, Asad Haider from Goldman Sachs maintained a Buy rating on Merck & Company, with a price target of $133.00. The company’s shares closed last Wednesday at $112.89.
According to TipRanks.com, Haider is a 4-star analyst with an average return of
Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $134.55, representing a 19.5% upside. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $142.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Regeneron (REGN)
In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron, with a price target of $967.00. The company’s shares closed last Wednesday at $746.58.
According to TipRanks.com, Richter is a 4-star analyst with an average return of
Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $874.76, representing a 16.4% upside. In a report issued on April 8, Bernstein also maintained a Buy rating on the stock with a $921.00 price target.
Read More on MRK:
